Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Alkermes PLCALKS15.723.703.9410.2427.90%17.19%0.00$34.71$315.5790,859$35.31

Detail of Alkermes PLC

 
CEO
Mr. Richard F. Pops
Employees
1800
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Market cap
$6B

Company details

Alkermes plc is a prominent biopharmaceutical company focusing on the development and commercialization of innovative medicines aimed at addressing unmet medical needs in major therapeutic areas such as neuroscience and oncology. As a leader in its field, Alkermes plc combines its scientific expertise with a commitment to improving patient outcomes, developing a pipeline of products that include treatments for serious conditions like schizophrenia, bipolar disorder, and alcohol and opioid dependence. The company distinguishes itself through its integrated approach to drug development, which includes a comprehensive system for clinical trial design, regulatory strategy, and formulation science. Alkermes plc plays a significant role in the healthcare market by bringing transformative therapies to patients worldwide, collaborating with academic institutions, pharmaceutical companies, and health organizations to expand the impact of its innovations. Headquartered in Dublin, Ireland, with research and manufacturing facilities in Massachusetts and Ohio, Alkermes plc leverages its multinational presence to advance its mission of making a positive difference in the lives of patients, while maintaining robust financial performance in the competitive biopharmaceutical landscape.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$1.56B
Cost of goods (CoG)
-$245.33M
Gross profit (GP)
$1.31B
Operating expense (OE)
-$890.56M
Research and development (R&D)
-$245.33M
General and administrative (G&A)
-$645.24M
Operating income (OI)
$420.64M
Other income expense (OIE)
-$3.24M
Pretax income (PI)
$443.75M
Tax (TAX)
-$71.61M
Net income (NI)
$367.07M
Alkermes PLC
ALKS • XNGS • US
$35.31
+8.31 (30.81%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$2.25
Margin profit
23.57%
52 week low
$23.01
52 week high
$36.406101
50-day simple moving average
$35.24
200-day simple moving average
$34.71
Percent held by insiders
1.67%
Percent held by institutions
105.84%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ALKS +29.28%
eps change
ALKS -100.00%